Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children29010.24287/1726-1708-2019-18-4-90-98CLINICAL OBSERVATIONSКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯLeptomeningeal canceromatosis in patient with parameningeal rhabdomyosarcomaДиссеминированное поражение мозговых оболочек при рабдомиосаркоме параменингеальной локализацииhttps://orcid.org/0000-0001-9450-125XKazakovaL. L.КазаковаЛ. Л.
Russian Federation

Correspondence: Lilia L. Kazakova, MD, doctor ‒ pediatric oncologist of the department of hematology/oncology of older age and neuro-oncology of Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare ofRussian Federation.

Address: Russia 117997, Moscow, Samory Mashela st., 1

Контактная информация: Казакова Лилия Леонидовна, врач – детский онколог отделения гематологии/онкологии старшего возраста и нейроонкологии НМИЦ детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России.

Адрес: 117997, Москва, ГСП-7, ул. Саморы Машела, 1lilia.leonidovna.kazakova@gmail.comhttps://orcid.org/0000-0002-9054-5068ZhukovN. V.ЖуковН. В.
Russian Federation

Moscow

Москва

Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииN.I. Pirogov Russian National Research Medical UniversityВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России3112201918490983012201930122019Copyright ©; 2019, «D. Rogachev NMRCPHOI»Copyright ©; 2019, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2019«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/290

The development of leptomeningeal carcinomatosis (LC) is quite a frequent event during a rhabdomyosarcoma with parameningeal localization, usually known as a parameningeal rhabdomyosarcoma (PM RMS). However, the diagnosis and treatment of this kind of progression are still difficult for pediatricians and pediatric oncologists due to the small absolute number of PM RMS patients, which makes it impossible to accumulate sufficient clinical experience, as well as due to the absence of a pathognomonic clinical picture and a standardized specific therapy. The article describes 3 clinical cases of LC during PM RMS and provides an overview of existing literature focusing on this problem. Parents patients agreed to use personal data in research and publications.

Развитие лептоменингеального канцероматоза (ЛМК) – достаточно частое событие при рабдомиосаркоме параменингеальной локализации (РМС ПМ). Однако диагностика и лечение данного вида прогрессирования до сих пор представляют трудности для педиатров и детских онкологов, что связано с малым абсолютным числом больных с РМС ПМ, не позволяющим накопить достаточный клинический опыт, отсутствием патогномоничной клинической картины и стандартизованной специфической терапии. В статье представлены описания трех клинических случаев развития ЛМК при РМС ПМ и обзор литературы, посвященный этой проблеме. Родители пациентов дали согласие на использование информации в научных исследованиях и публикациях.

leptomeningeal carcinomatosisa disseminated lesion of the meningesparameningeal rhabdomyosarcomahead and neck tumorschildrenлептоменингеальный канцероматоздиссеминированное поражение мозговых оболочекрабдомиосаркома параменингеальной локализацииопухоли головы и шеидети1. Carli M., Cecchetto G., Sotti G. Soft Tissue Sarcomas In: Pediatric Oncology. R Pinkerton, PN Plowman, R Pieters (Eds). 2004; London. Arnold, 339–70.Carli M., Cecchetto G., Sotti G. Soft Tissue Sarcomas In: Pediatric Oncology. R Pinkerton, PN Plowman, R Pieters (Eds). 2004; London. Arnold, 339–70.2. Miller R.W., Young J.L. Jr., Novakovic B. Childhood cancer. Cancer 1995; 75: 395–405. DOI: 10.1002/1097-0142.Miller R.W., Young J.L. Jr., Novakovic B. Childhood cancer. Cancer 1995; 75: 395–405. DOI: 10.1002/1097-0142.3. Siegel R.L., Miller K.D., Ahmedin J. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34. DOI: 10.3322/caac.21551.Siegel R.L., Miller K.D., Ahmedin J. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34. DOI: 10.3322/caac.21551.4. Yang B.A., Wexler L.H., Meyers P.A., Wolden S.L. Parameningeal Rhabdomyosarcoma: Outcomes and Opportunities. Int J Radiat Oncol Biol Phys 2013; 61–6. DOI: 10.1016/j.ijrobp.2012.08.019Yang B.A., Wexler L.H., Meyers P.A., Wolden S.L. Parameningeal Rhabdomyosarcoma: Outcomes and Opportunities. Int J Radiat Oncol Biol Phys 2013; 61–6. DOI: 10.1016/j.ijrobp.2012.08.0195. Grewal J., Harpreet K., Grewal M.D. Leptomeningeal metastasis Copyright© 2001–2018 MedLink Corporation. All rights reserved.Grewal J., Harpreet K., Grewal M.D. Leptomeningeal metastasis Copyright© 2001–2018 MedLink Corporation. All rights reserved.6. Li Y.-S., Jiang B.-Y., Yang J.-J., Tu H.Y., Zhou Q., Guo W.B. Leptomeningeal meta-stases in non-small cell lung cancer patients with EGFR mutations. Journal of Thoracic Oncology 2016. DOI: 10.1016/j.jtho.2016.06.029.Li Y.-S., Jiang B.-Y., Yang J.-J., Tu H.Y., Zhou Q., Guo W.B. Leptomeningeal meta-stases in non-small cell lung cancer patients with EGFR mutations. Journal of Thoracic Oncology 2016. DOI: 10.1016/j.jtho.2016.06.029.7. Chan R.C., Wataru W. Parameningeal Rhabdomyosarcoma. Radiology 1979 Apr; 131: 211–4. DOI: 10.1148/131.1.211.Chan R.C., Wataru W. Parameningeal Rhabdomyosarcoma. Radiology 1979 Apr; 131: 211–4. DOI: 10.1148/131.1.211.8. Kesari S., Batchelor T.T. Leptomeningeal metastases. Neurol Clin N AmKesari S., Batchelor T.T. Leptomeningeal metastases. Neurol Clin N Am2013; 21: 25–66. DOI: 10.1016/s0733-8619(02)00032-4.; 21: 25–66. DOI: 10.1016/s0733-8619(02)00032-4.9. Gleissner B., Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 2006; 5: 443–52. DOI: 10.1016/s1474-4422(06)70443-4Gleissner B., Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 2006; 5: 443–52. DOI: 10.1016/s1474-4422(06)70443-410. O’Meara W.P., Borkar S.A., Stambuk H.E., Lymberis S.C. Leptomeningeal metastasis. Curr Probl Cancer 2007; 31: 372–424. DOI: 10.1016/j.currproblcancer.2007. 07.001.O’Meara W.P., Borkar S.A., Stambuk H.E., Lymberis S.C. Leptomeningeal metastasis. Curr Probl Cancer 2007; 31: 372–424. DOI: 10.1016/j.currproblcancer.2007. 07.001.11. Siegal T., Lossos A., Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463–9. DOI: 10.1212/wnl.44.8.1463.Siegal T., Lossos A., Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463–9. DOI: 10.1212/wnl.44.8.1463.12. Chamberlain M.C., Kormanik P.A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694–9. DOI: org/10.3171/jns.1997.87.5.0694.Chamberlain M.C., Kormanik P.A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694–9. DOI: org/10.3171/jns.1997.87.5.0694.13. Berg S.L., Chamberlain M.C. Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 2005; 125: 121–46. DOI: 10.1007/0-387-24199-x_8.Berg S.L., Chamberlain M.C. Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 2005; 125: 121–46. DOI: 10.1007/0-387-24199-x_8.14. Berg S.L., Chamberlain M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 2003; 5: 29–40. DOI: 10.1007/s11912-003-0084-9.Berg S.L., Chamberlain M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 2003; 5: 29–40. DOI: 10.1007/s11912-003-0084-9.15. Leal T., Chang J.E., Mehta M., Robins H.I. Leptomeningeal Metastasis. Challenges in Diagnosis and Treatment. Current Cancer Therapy Reviews 2011; 7: 319–27. DOI: 10.2174/157339411797642597.Leal T., Chang J.E., Mehta M., Robins H.I. Leptomeningeal Metastasis. Challenges in Diagnosis and Treatment. Current Cancer Therapy Reviews 2011; 7: 319–27. DOI: 10.2174/157339411797642597.16. Meazza C., Ferrari A., Casanova M. Evolving treatment strategies for parameningeal Rhabdomyosarcoma: the experience of the istituto Nazionale tumori of milan. Accepted 18 June 2004. Published online 4 November 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/hed.20117Meazza C., Ferrari A., Casanova M. Evolving treatment strategies for parameningeal Rhabdomyosarcoma: the experience of the istituto Nazionale tumori of milan. Accepted 18 June 2004. Published online 4 November 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/hed.2011717. Harris P., Diouf A., Guilbert F., Ameur F., Letourneau-Guillon L., Ménard C. Diagnostic Reliability of Leptomeningeal Disease Using Magnetic Resonance Imaging. Cureus 2019 Apr 9; 11 (4): e4416. DOI: 10.7759/cureus.4416Harris P., Diouf A., Guilbert F., Ameur F., Letourneau-Guillon L., Ménard C. Diagnostic Reliability of Leptomeningeal Disease Using Magnetic Resonance Imaging. Cureus 2019 Apr 9; 11 (4): e4416. DOI: 10.7759/cureus.441618. Ho-Shin Gwak, Sang Hyun Lee, Weon Seo Park, Sang Hoon Shin, Heon Yoo, Seung Hoon Lee. Recent Advancements of Treatment for Leptomeningeal Carcinomatosis. Journal of Korean Neurosurgical Society 2015; 58: 1. DOI: 10.3340/jkns.2015.58.1.1Ho-Shin Gwak, Sang Hyun Lee, Weon Seo Park, Sang Hoon Shin, Heon Yoo, Seung Hoon Lee. Recent Advancements of Treatment for Leptomeningeal Carcinomatosis. Journal of Korean Neurosurgical Society 2015; 58: 1. DOI: 10.3340/jkns.2015.58.1.119. Jorda M., Ganjei-Azar P., Nadji M. Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 1998; 55: 181–4. DOI: 10.1001/archneur.55.2.181Jorda M., Ganjei-Azar P., Nadji M. Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 1998; 55: 181–4. DOI: 10.1001/archneur.55.2.18120. Bruna J., Gonzalez L., Miro J., Velasco R., Gil M., Tortosa A. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009, 115: 381–9. DOI: 10.1002/cncr.24041Bruna J., Gonzalez L., Miro J., Velasco R., Gil M., Tortosa A. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009, 115: 381–9. DOI: 10.1002/cncr.2404121. Le Rhun E., Preusser M., van den Bent M., Andratschke N., Weller M. How we treat patients with leptomeningeal metastases. ESMO Open 2019. DOI: 10.1136/esmoopen-2019-000507Le Rhun E., Preusser M., van den Bent M., Andratschke N., Weller M. How we treat patients with leptomeningeal metastases. ESMO Open 2019. DOI: 10.1136/esmoopen-2019-000507